MSD Italia S.R.L.
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
20
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 16, 2026The maintenance fee for Hepatitis C Virus Nucleic Acid Vaccine (US 9,056,090) comes due Dec 16, 2026. Unpaid by Jun 16, 2027, it lapses early.
Recent changes
- 3 terms have ended since Aug 23, 2026
- Oct 10 US 7,939,537 HIV Integrase Inhibitors · term ended
- Oct 10 US 7,863,294 Heterocycle Derivatives as Histone Deacetylase (HDAC) Inhibitors · term ended
- Oct 3 US 8,492,522 Matrix metalloproteinase 11 vaccine · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,799,825 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors In force · High confidence | In force | High confidence | |
| US 8,106,176 | Matrix Metalloproteinase 11 Vaccine In force · High confidence | In force | High confidence | |
| US 8,216,834 | Chimpanzee Adenovirus Vaccine Carriers In force · High confidence | In force | High confidence | |
| US 8,080,573 | Heterocycle Substituted Amide and Sulfur Amide Derivatives as Histone Deacetylase (HDAC) Inhibitors In force · High confidence | In force | High confidence | |
| US 7,977,374 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors In force · High confidence | In force | High confidence | |
| US 8,026,265 | Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors In force · High confidence | In force | High confidence | |
| US 7,981,879 | HIV Integrase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,178,520 | Macrocyclic Compounds as Antiviral Agents In force · High confidence | In force | High confidence | |
| US 7,781,422 | Antiviral Indoles In force · High confidence | In force | High confidence | |
| US 7,767,660 | Antiviral Indoles In force · High confidence | In force | High confidence |
Also on record, not counted in the 20: 15 patents in force now held by others · 7 lapsed for an unpaid fee · 19 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.